Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.74 [0.60, 0.91] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 1.00 [0.82, 1.21] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | important | - |
DCR | 0.57 [0.38, 0.87] | | > 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 0.88 [0.64, 1.22] | | > 1 | | 0% | 1 study (1/-) | 21.8 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
STRAE (any grade) | 0.92 [0.65, 1.31] | | < 1 | | 0% | 1 study (1/-) | 67.2 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 2.86 [0.30, 27.64] | | < 1 | | 0% | 1 study (1/-) | 18.4 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 1.59 [1.05, 2.41] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (grade 3-4) | 2.21 [1.28, 3.81] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.47 [0.02, 14.14] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Acute kidney injury TRAE (grade 3-4) | 7.66 [0.40, 145.59] | | < 1 | | 0% | 1 study (1/-) | 9.0 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 1.90 [0.06, 56.75] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.03 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 1.90 [0.06, 56.75] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Arthritis TRAE (grade 3-4) | 3.81 [0.17, 84.75] | | < 1 | | 0% | 1 study (1/-) | 20.2 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.04 [0.00, 0.64] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 6.76 [0.83, 55.31] | | < 1 | | 0% | 1 study (1/-) | 3.8 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.47 [0.02, 14.14] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.95 [0.13, 6.76] | | < 1 | | 0% | 1 study (1/-) | 52.2 % | NA | not evaluable | | non important | - |
Dermatitis acneiform TRAE (grade 3-4) | 1.90 [0.06, 56.75] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 4.86 [1.06, 22.39] | | < 1 | | 0% | 1 study (1/-) | 2.1 % | NA | not evaluable | | non important | - |
Dyspnoea TRAE (grade 3-4) | 0.47 [0.02, 14.14] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.56 [0.13, 2.38] | | < 1 | | 0% | 1 study (1/-) | 78.2 % | NA | not evaluable | | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.16 [0.01, 3.14] | | < 1 | | 0% | 1 study (1/-) | 88.5 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 3.81 [0.17, 84.75] | | < 1 | | 0% | 1 study (1/-) | 20.2 % | NA | not evaluable | | non important | - |
Hypersensitivity TRAE (grade 3-4) | 1.90 [0.06, 56.75] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.95 [0.02, 47.87] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 5.73 [0.29, 114.85] | | < 1 | | 0% | 1 study (1/-) | 13.0 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 9.61 [0.52, 176.72] | | < 1 | | 0% | 1 study (1/-) | 6.6 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 11.79 [1.52, 91.29] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 5.73 [0.29, 114.85] | | < 1 | | 0% | 1 study (1/-) | 13.0 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 1.90 [0.06, 56.75] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.24 [0.01, 5.24] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
Myocarditis TRAE (grade 3-4) | 1.90 [0.06, 56.75] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 3.81 [0.17, 84.75] | | < 1 | | 0% | 1 study (1/-) | 20.2 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.13 [0.02, 1.08] | | < 1 | | 0% | 1 study (1/-) | 97.0 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.04 [0.01, 0.16] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Pancytopenia TRAE (grade 3-4) | 0.09 [0.01, 1.71] | | < 1 | | 0% | 1 study (1/-) | 94.3 % | NA | not evaluable | | non important | - |
Pneumonia TRAE (grade 3-4) | 0.47 [0.02, 14.14] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 1.90 [0.06, 56.75] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 5.73 [0.29, 114.85] | | < 1 | | 0% | 1 study (1/-) | 13.0 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.47 [0.02, 14.14] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 5.73 [0.29, 114.85] | | < 1 | | 0% | 1 study (1/-) | 13.0 % | NA | not evaluable | | non important | - |
Sepsis TRAE (grade 3-4) | 0.47 [0.02, 14.14] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.47 [0.02, 14.14] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.18 [0.04, 0.85] | | < 1 | | 0% | 1 study (1/-) | 98.5 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.08 [0.00, 1.39] | | < 1 | | 0% | 1 study (1/-) | 95.7 % | NA | not evaluable | | non important | - |